Myungmoon Phar
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hype… Read more
Myungmoon Phar - Asset Resilience Ratio
Myungmoon Phar (017180) has an Asset Resilience Ratio of 0.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how Myungmoon Phar's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Myungmoon Phar's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩280.03 Million | 0.1% |
| Total Liquid Assets | ₩280.03 Million | 0.10% |
Asset Resilience Insights
- Limited Liquidity: Myungmoon Phar maintains only 0.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Myungmoon Phar Industry Peers by Asset Resilience Ratio
Compare Myungmoon Phar's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Myungmoon Phar (2009–2024)
The table below shows the annual Asset Resilience Ratio data for Myungmoon Phar.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.14% | ₩365.41 Million | ₩257.99 Billion | -1.42pp |
| 2023-12-31 | 1.57% | ₩3.70 Billion | ₩236.55 Billion | -0.66pp |
| 2022-12-31 | 2.22% | ₩5.13 Billion | ₩230.45 Billion | +0.56pp |
| 2021-12-31 | 1.66% | ₩3.70 Billion | ₩222.68 Billion | -1.85pp |
| 2020-12-31 | 3.51% | ₩8.53 Billion | ₩243.03 Billion | +0.41pp |
| 2019-12-31 | 3.10% | ₩8.19 Billion | ₩264.44 Billion | -0.35pp |
| 2018-12-31 | 3.45% | ₩8.39 Billion | ₩243.07 Billion | +0.29pp |
| 2017-12-31 | 3.16% | ₩7.43 Billion | ₩235.08 Billion | +1.07pp |
| 2016-12-31 | 2.09% | ₩4.62 Billion | ₩221.08 Billion | -0.97pp |
| 2015-12-31 | 3.07% | ₩6.11 Billion | ₩199.42 Billion | -1.22pp |
| 2014-12-31 | 4.28% | ₩8.17 Billion | ₩190.66 Billion | -0.35pp |
| 2013-12-31 | 4.64% | ₩8.92 Billion | ₩192.41 Billion | +0.53pp |
| 2012-12-31 | 4.10% | ₩7.73 Billion | ₩188.34 Billion | +1.93pp |
| 2011-12-31 | 2.18% | ₩4.41 Billion | ₩202.50 Billion | -3.91pp |
| 2010-12-31 | 6.08% | ₩9.99 Billion | ₩164.15 Billion | +5.50pp |
| 2009-12-31 | 0.58% | ₩890.00 Million | ₩153.85 Billion | -- |